F15063, a potential antipsychotic with D 2/D 3 antagonist, 5-HT 1A agonist and D 4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 237-252

  Newman Tancredi, A ^a   Assie M B ^a   Martel, J C ^a   Cosi, C ^a   Slot, L Bruins ^a   Palmier, C ^a   Rauly Lestienne, I ^a   Colpaert, F ^a   Vacher, B ^a   Cussac, D ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotic; Autoradiography; Dopamine D 2; Dopamine D 4; ERK1 2 phosphorylation; G protein; Serotonin 5 HT 1A

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BENZOFURAN DERIVATIVE; CYCLIC AMP; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; F 15063; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; HISTAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOAMINE; N [(2,2 DIMETHYL 2,3 DIHYDROBENZOFURAN 7 YLOXY)ETHYL] 3 (CYCLOPENT 1 ENYL)BENZYLAMINE; NEUROLEPTIC AGENT; PARTIAL AGONIST; QUINELORANE; RADIOLIGAND; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CELL LINE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR AFFINITY; SEPTUM PELLUCIDUM; SIGNAL TRANSDUCTION; TARGET VARIABLE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; BENZYLAMINES; BINDING, COMPETITIVE; CELL LINE; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; CYCLOPENTANES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MALE; MOLECULAR STRUCTURE; PHOSPHORYLATION; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; SEROTONIN AGONISTS; SPODOPTERA; SWINE;

EID: 34247892865     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707158     Document Type: Article

References (85)

1. 1A receptors. Br J Pharmacol 130: 1348-1352.
2. 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical DA and hippocampal serotonin release in rat brain. J Pharmacol Expt Ther 315: 265-272.
3. 1A affinity in rodent models of cognitive flexibility and sensory gating: II) The reversal learning task and PPI of the startle reflex. Int J Neuropsychopharmacol 9 (Supp 1): P01.167.
4. 2 receptor blockade. Neuropsychopharmacol 31: 1900-1909.
5. 1D receptors. Neuropsychopharmacol 25: 410-422.
6. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37-46.
7. 7) positively linked to adenylate cyclase. J Biol Chem 268: 23422-23426.
8. 1A agonist properties. Neuropsychopharmacology 31: 1869-1879.
9. 1A affinity in rodent models of cognition and memory deficits: (I) The hole-board and the social recognition tests. Int J Neuropsychopharmacol 9 (Suppl 1): P01.166.
10. 4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav Brain Res 142 (1-2): 41-52.
11. 1A agonists in the treatment of depression? Biol Psychiatry 53: 193-203.
12. 4 agonist, improves cognitive performance in rats. Pharmacol Biochem Behav 82: 148-155.
13. Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB (2005). Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry 57: 617-623.
14. 2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534: 63-70.
15. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacol 49: 996-1006.
16. 2A receptors in depression. Rev Psychiatry Neurosci 29: 252-265.
17. 1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28: 2064-2076.
18. Cosi C, Carilla-Durand E, Assié MB, Ormière AM, Maraval M, Leduc N et al. (2006). Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535: 135-144.
19. 1A receptor activities. J Med Chem (in press).
20. 1A receptors. Psychopharmacology 162: 168-177.
21. 2C receptors revealed by antibody capture assays: Influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62: 578-589.
22. 2 receptors. Eur J Pharmacol 394: 47-50.
23. 1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res 989: 42-51.
24. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
25. De Vries P, Apaydin S, Villalon CM, Heiligers JP, Saxena PR (1997). Interactions of GR127935, a 5-HT(1B/D) receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 355: 423-430.
26. 3 receptors enhances frontocortical cholinergic transmission and cognitive function in rats. Am Soc Neurosci Abstr 30: 776.4.
27. Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven M, Newman-Tancredi A (2007a). F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (III) activity in models of cognition and negative symptoms. Br J Pharmacol [E-pub ahead of print: 20 March 2007; doi:10.1038/sj.bjp.0707160].
28. 4 partial agonist properties: (II) Behavioural profile in models of positive, negative symptoms and cognitive deficits of schizophrenia. Int J Neuropsychopharmacol 9 (Supp 1): P01.165.
29. Depoortère R, Bardin L, Auclair AL, Kleven M, Prinssen E, Newman-Tancredi A (2007b). F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia. Br J Pharmacol [E-pub ahead of print: 20 March 2007; doi:10.1038/sj.bjp.0707159].
30. 1A receptor agonist. II: behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28: 1889-1902.
31. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831-10843.
32. 1A receptor. J Biol Chem 264: 14848-14852.
33. 1A receptor agonist: in vitro and in vivo neuropharmacology. Eur Neuropsychopharmacol 12 (Suppl 3): P.2.053.
34. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychoparmacol 11: 193-197.
35. 3H]- RX821002: a highly selective ligand for the identification of α2-adrenoceptors in the rat brain. Mol Neuropharmacol 1: 219-229.
36. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858: 252-263.
37. 1A agonist, blocks haloperidol-induced catalepsy by an action of raphe nuclei medianus and dorsalis. Neuropharmacology 27: 515-518.
38. Jentsch JD, Taylor JR, Redmond Jr DE, Elsworth JD, Youngren KD, Roth RH (1999). Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 142: 78-84.
39. 1A receptors. Eur Neuropsychopharmacol 12: S293.
40. 3 receptor antagonists as therapeutic agents. Drug Disc Today 10: 917-925.
41. 2 antagonist/partial agonist properties: in vitro characterisation. Int J Neuropsychopharmacol 9 (Suppl 1): P02.213.
42. 1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282: 747-759.
43. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacol 49: 135-143.
44. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179: 567-575.
45. Lazareno S, Birdsall NJ (1993). Estimation of antagonist Kb from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol Sci 14: 237-239.
46. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45: 174-181.
47. Leucht S, Wahlbeck K, Hamann J, Kissling W(2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581-1589.
48. Leysen J (2000). Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (eds). Atypical Antipsychotics. Birkhäuser Verlag: Basel, Switzerland, pp 57-81.
49. Li Z, Ichikawa J, Dai J, Meltzer HY (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493: 75-83.
50. 1A receptors show constitutive activity. Mol Pharmacol 71: 638-643.
51. 1A receptor agonist BAY x 3702 in vitro and in vivo. Brain Res 888: 150-157.
52. McCreary AC, Glennon J, Tuinstra T, Herremans AHJ, Van der Heyden JAM, Feenstra R et al. (2002). SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like actions. Eur Neuropsychopharmacol 12 (Suppl 3): P.2.046.
53. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 27: 1159-1172.
54. Meltzer HY, Park S, Kessler R (1999). Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 96: 13591-13593.
55. 1A receptors. J Pharmacol Exp Ther 295: 853-861.
56. Millan MJ, Dekeyne A, Rivet J-M, Dubuffet T, Lavielle G, Brocco M (2000). S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-Receptors: II. functional and behavioural profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293: 1063-1073.
57. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002a). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804.
58. 3H]GR125,743: a pharmacological characterisation. Pharmacol Biochem Behaviour 71: 589-598.
59. Newman-Tancredi A, Assie MB, Leduc N, Ormière AM, Danty N, Cosi C (2005). Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8: 1-16.
60. 4 partial agonist properties: (I) in vitro, neurochemical and neuroendocrine profiles. Int J Neuropsychopharmacol 9 (Suppl 1): P01.164.
61. 4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282: 181-191.
62. 2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 920: 41-54.
63. 1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol 368: 188-199.
64. Pauwels PJ, Rauly I, Wurch T (2003). Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated alpha2A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism. J Pharmacol Exp Ther 305: 1015-1023.
65. Pauwels PJ, Tardif S, Palmier C, Wurch T, Colpaert FC (1997). How efficacious are 5-HT1B/D receptor ligands: an answer from GTPgammaS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36: 499-512.
66. Pazos A, Hoyer D, Palacios JM (1985a). Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur J Pharmacol 106: 531-538.
67. Pazos A, Hoyer D, Palacios JM (1985b). The binding of serotonergic ligands to the porcine choroid plexus: characterisation of a new type of serotonin recognition site. Eur J Pharmacol 106: 539-546.
68. Pedersen UB, Norby B, Jensen AA, Schiodt M, Hansen A, Suhr-Jessen P et al. (1994). Characteristics of stably expressed human dopamine D1a and D1b receptors: atypical behavior of the dopamine D1b receptor. Eur J Pharmacol 15: 85-93.
69. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453: 217-221.
70. 7 receptors coupled to adenylyl cyclase activity. Fund Clin Pharmacol 18 (Suppl 1): Poster 05.37.
71. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294: 1154-1165.
72. 1A receptor activation. Eur J Pharmacol 338: R3-R5.
73. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev Drug Disc 3: 353-359.
74. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
75. Silver H, Feldman P, Bilker W, Gur RC (2003). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 160: 1809-1816.
76. 1D receptor antagonist. Behav Brain Res 73: 157-161.
77. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disorders - Drug Targets 5: 25-43.
78. Sovner R, Parnell-Sovner N (1989). Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 9: 61-62.
79. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al. (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722-1725.
80. 1A agonist, on memory function in schizophrenia. Biol Psychiatry 49: 861-868.
81. Vacher B, Cuisiat S, Koek W, Colpaert F (2002). 3-(Cyclopenten-1-yl)- benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia. Patent no. WO 2004/035561 A1. Priority 16 October 2002.
82. 2 receptors in vitro. Eur J Neuropsychopharmacol 10 (Suppl 3): P.2.035.
83. 1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23: 547-559.
84. Wurch T, Colpaert FC, Pauwels PJ (1999). G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors. Br J Pharmacol 126: 939-948.
85. 4 receptor in rats. Neuropsychopharmacology 29: 1648-1655.